Carson Wealth (CWM LLC)
ZNTL icon

Carson Wealth (CWM LLC)’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Carson Wealth (CWM LLC)’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.6K Sell
5,377
-3,187
-37% -$8.23K ﹤0.01% 4688
2025
Q4 		$12K Sell
8,564
-4,554
-35% -$6.63K ﹤0.01% 4477
2025
Q3 		$20K Sell
13,118
-15,528
-54% -$23.3K ﹤0.01% 4135
2025
Q2 		$33K Sell
28,646
-11,053
-28% -$14.6K ﹤0.01% 3599
2025
Q1 		$63K Buy
39,699
+34,889
+725% +$75.2K ﹤0.01% 2787
2024
Q4 		$15K Buy
4,810
+2,379
+98% +$7.8K ﹤0.01% 3648
2024
Q3 		$9K Buy
2,431
+2,356
+3,141% +$8.56K ﹤0.01% 3862
2024
Q2 		$0 Buy
75
+36
+92% +$402 ﹤0.01% 4993
2024
Q1 		$1K Buy
+39
New +$536 ﹤0.01% 4248
2023
Q4 		– Sell
-137
Closed -$3K – 4567
2023
Q3 		$3K Hold
137
– – ﹤0.01% 3724
2023
Q2 		$4K Buy
+137
New +$3.29K ﹤0.01% 3578
2022
Q2 		– Sell
-7
Closed – – 4130
2022
Q1 		$0 Sell
7
-12
-63% -$647 ﹤0.01% 3911
2021
Q4 		$2K Buy
+19
New +$1.47K ﹤0.01% 3207

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Carson Wealth (CWM LLC)'s ZNTL Position: Q1 2026 in Review

Carson Wealth (CWM LLC) reduced its Zentalis Pharmaceuticals (ZNTL) stake by 37% in Q1 2026, selling an estimated $8.23K and leaving 5,377 shares worth $12.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4688.

Carson Wealth (CWM LLC) first reported a position in ZNTL in Q4 2021 and has held it in 13 quarters since. The position peaked at $63K in Q1 2025. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Carson Wealth (CWM LLC) held 5,377 shares of Zentalis Pharmaceuticals worth $12.6K as of Q1 2026.
  • Carson Wealth (CWM LLC) sold 3,187 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $8.23K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Carson Wealth (CWM LLC)'s portfolio in Q1 2026, its #4688 holding.
  • Carson Wealth (CWM LLC) first reported a position in Zentalis Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
  • Carson Wealth (CWM LLC)'s Zentalis Pharmaceuticals position peaked at $63K in Q1 2025.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q1 2026, filed 14 May 2026.